Meeting
2022 ASCO Annual Meeting
CoRInTH: A phase Ib/II trial of checkpoint inhibitor, pembrolizumab (PD-1 antibody [Ab]) plus standard intensity modulated chemoradiotherapy (IMCRT) in HPV-induced stage III squamous cell carcinoma (SCC) of the anus.
Authors
Marcia Hall
Mount Vernon Cancer Centre, Northwood, United Kingdom
Marcia Hall , Richard Adams , Marianne Grønlie Guren , Margherita Carucci , Lisette Nixon , Catharine Porter , Neel Bhuva , Robert Glynne-Jones , Mark Harrison
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Anal Cancer
Clinical Trial Registration Number
NCT04046133
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3630)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3630
Abstract #
TPS3630
Poster Bd #
423a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer.
First Author: Linda R. Duska
Poster
2017 Gastrointestinal Cancers Symposium
Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer.
First Author: Irene S. Yu
Poster
2016 ASCO Annual Meeting
Phase IB study of pembrolizumab in combination with chemoradiotherapy (CRT) for locally-advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
First Author: Steven Francis Powell
Poster
2024 ASCO Annual Meeting
Safety and feasibility of esophagectomy following neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: Analysis of two phase 2 clinical trials.
First Author: dijian shen